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Abstract: Lentiviral gene delivery is now considered as a major candidate in the future of cancer therapy. To avoid common side-effects
associated with methods of cancer therapy, the survivin promoter shows great promise due to its high expression level in multiple
cancers. In this research, using a 2A peptide, Noxa was coexpressed with hemagglutinin neuraminidase (HN) driven by the survivin
promoter (Surp). Coding genes of Noxa and HN were connected to the upstream and downstream of a 2A peptide using SOE PCR.
After cloning of Noxa-2A-HN and Surp into the lentiviral vector, the final construct was transfected to SK-BR3 tumor cells and human
embryonic kidney 293T cells. Quantitative real-time PCR implied efficient transfection and integration of the lentiviral vector in target
cells. Western blotting analysis was performed to verify the expression of Noxa and HN and we determined cell viability by MTT
calorimetric assay after transfection. Our results showed that the expression of Noxa and HN, though not utterly specific, was relatively
higher in tumor cells and led to the selective suppression of tumor cells, which eventually resulted in a cell survival reduction of 76%. In
conclusion, the novel pLN2AH-Surp lentiviral vector proved the potential for further in vivo and clinical experiments.
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1. Introduction
Gene therapy plays an imperative role in the postgenomic
fight against cancer. Because of the costs and time involved
in producing and manufacturing monoclonal antibodies
as the primary biological agents for cancer therapy and
the indefinite demand for follow-up treatment, alternative
platforms including immunotherapy and genetic delivery
of therapeutics have been extensively investigated in recent
years (Kafri et al., 2000; Liechtenstein et al., 2013). With
their clinical studies recently having started (Levine et al.,
2006), lentiviral vectors are now considered as effective
means for the delivery, integration, and expression of
exogenous genes in mammalian cells, providing attractive
gene delivery vehicles in the context of both dividing and
nondividing cells. These vectors have proven to be useful in
stably transducing brain (Naldini et al., 1996), liver (Kafri et
al., 1997), heart (Zhao et al., 2002), and retinal (Miyoshi et
al., 1997) cells in vivo without toxicity or immune responses.
Various strategies are applied in viral vectors to coexpress
multiple genes, including dual promoters, mRNA splicing,
internal ribosomal entry sites (IRES), and fusion proteins.
Due to several disadvantages attributed to the mentioned
methods, other possibilities have been investigated, of
which viral-based 2A peptides have proven to be the best
* Correspondence: r.dorost@yahoo.com

option (Luke, 2012; Yan et al., 2015). Many positive-strand
RNA viruses including foot-and-mouth disease virus (F2A),
porcine teschovirus-1 (P2A), and Thosea asigna virus (T2A)
generally contain 2A or similar peptide coding sequences to
mediate protein cleavage through a theoretically described
ribosomal skip mechanism in order to produce several
proteins from a single polypeptide (Luke, 2012). The
cleavage occurs at the C-terminal end of the 2A peptide,
leaving it fused to the upstream protein and releasing the
downstream protein with the addition of an N-terminal
proline, which generally does not appear to significantly
affect the function of the fused protein. Previously, different
2A peptides have been successfully incorporated into AAV
and retroviral vectors to construct multicistronic vectors
(Yang et al., 2008; Li et al., 2012; Dong et al., 2015).
Showing high and specific activity in multiple cancers,
the survivin promoter is a valuable tool in gene therapy
to drive specific expression of toxic genes in cancer cells.
Survivin has been efficiently used in several previous studies
to specifically suppress various tumor cells with minimum
impact on normal cells, which is considered an essential
characteristic for an effective method of cancer therapy
(Ambrosini et al., 1997; Yamamoto and Tanigawa, 2001;
Chen et al., 2004).
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The p53 tumor-suppressor gene, functionally
inactivated in approximately 50% of human tumors,
has been extensively studied for gene therapy purposes.
Activation of p53 by harmful stimuli such as DNA damage,
hypoxia, and oncogenes normally leads to cell cycle arrest
followed by DNA repair or induction of apoptosis as
a cellular response. Apoptosis is induced by BH3-only
proteins of the Bcl-2 family, of which Noxa and Puma
have been well characterized (Shibue et al., 2006; Wang et
al., 2009; Nakajima and Tanaka, 2011; Zhang et al., 2013).
These two proteins function in cooperation as downstream
factors to promote p53-mediated apoptotic response, with
the distinction of Noxa selectively inducing apoptosis
only in cancerous cells upon increased expression of other
proapoptotic factors such as Bax and consequently more
cell sensitivity, whereas Puma induces apoptosis in both
transformed and untransformed cells. Thus, in contrast
to most suicide genes commonly used in gene therapy
applications, Noxa shows negligible side-effects on normal
cells (Shibue et al., 2003, 2006; Suzuki et al., 2009). In this
experiment, Noxa was introduced in combination with
the hemagglutinin-neuraminidase (HN) of Newcastle
disease virus (NDV) to enhance the inhibitory effects.
As an immune adjuvant, by hydrolyzing sialic acid on
the surface of host cells, HN can decompose sialic acidcontaining receptors, expose the biological recognition
sites of host cells, stimulate innate immune responses
through increased natural killer (NK) cell activity in the
tumor niche, and, finally, promote the release of new virus
particles from the infected cell membrane (Ni et al., 2010,
2011; Ji et al., 2013; He et al., 2014).
Expecting the potential synergistic effect of survivin as
a tumor-specific promoter and Noxa as a tumor-specific
suicide gene coupled with HN as a molecular adjuvant,
we hoped to achieve maximal and minimal apoptotic
induction respectively in tumor cells and normal cells.
2. Materials and methods
2.1. Plasmids
The coding sequences of Noxa, hemagglutinin
neuraminidase (HN), and survivin promoter (Surp) were
PCR-amplified by proper primers. Using SOE PCR,
amplified genes of Noxa (192 bp) and HN (1764 bp)
were connected to the upstream and downstream of a 2A
connecting peptide, respectively, to form the Noxa-2AHN fusion gene of 1956 bp. Construction of the lentiviral
vector pLN2AH-Surp was accomplished by cloning 1430
bp of the Surp gene, which was cloned into the vector,

cutting out the original CMV promoter, using BamHI
and SfiI restriction enzymes on both the vector and the
amplified Surp gene. The order of genes and the survivin
promoter is illustrated in Figure 1. Two helper plasmids,
pMD2.G and psPAX2 (Addgene, USA), were used in this
study, which helped with the virus particle packaging.
2.2. Cell culture
The human breast cancer cell line SK-BR-3 and human
normal embryonic kidney (HEK) 293T cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM, SigmaAldrich, USA) supplemented with 10% FBS (SigmaAldrich, USA), 100 U/mL penicillin, and 100 mg/mL
streptomycin and incubated in 5% CO2 at 37 °C. During
passages, the cells were rinsed twice with 3 mL of PBS
buffer (room temperature). To stablish the recombinant
stable cell lines, 1.5 µg/mL puromycin was added to the
culture medium. Digestion was conducted with a 0.25%
trypsin solution at 37 °C for 2–3 min and terminated
with 3 mL of DMEM culture solution (10% FBS). The day
before transfection, 4 × 106 HEK-293T or SK-BR-3 cells
were seeded in 100-mm culture dishes containing 10 mL
of DMEM. On the day of transfection, the culture medium
was replaced with 10 mL of normal growth medium
containing serum without antibiotics. The respective
cell lines were harvested at 1000 rpm and tested for cell
viability and apoptosis at 1, 2, and 4 days after transfection.
2.3. Recombinant lentivirus packaging and titration
The lentiviral vector was packaged adopting the threeplasmid packaging system (Durocher et al., 2002). After
purifying the three plasmids to adequate concentrations
using the PureLink Quick Plasmid Miniprep Kit
(Invitrogen, USA), a mix of the three plasmids and
appropriate buffers was made as follows: a solution of
0.5 mL was first prepared consisting of 10.5 µg of shuttle
plasmid pMD2.G, 21 µg of packaging plasmid psPAX2, 21
µg of pLN2AH-Surp (or pLEX as a control empty vector)
plasmid DNA, and 125 µL of 2 mM CaCl2 and 0.5 mM
HEPES in deionized distilled water, which was then added
dropwise while vortexing to an equal volume of 2X HBS for
a total of 1 mL. This mix was added to dishes at an MOI of
100 (100 viral genomes per cell), determined by real-time
PCR using the primers FNox: 3’-atgcctgggaagaaggcgcg-5’
and RNox: 3’-tcaggttcctgagcagaagag-5’, as described
elsewhere (Salmon and Trono, 2007), and the cells were
maintained in 5% CO2 at 37 °C. After 24 h, the transduced
cells were trypsinized, collected at 1000 rpm, and
resuspended with DMEM. The packaged recombinant
lentiviruses were harvested from the supernatant of cell

Figure 1. Diagram of the Noxa-2A-HN construct under the control of the survivin promoter.
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cultures at 48 h after transfection and the lentivirus RNA
was prepared with the RNeasy Mini Kit (QIAGEN, USA)
and then treated by DNase I (Roche, the Netherlands)
digestion.
2.4. Expression analysis
Quantitative real-time PCR was performed on extracted
RNA of respective transformed cell lines to confirm
the expression of the Noxa-2A-HN gene using specific
primers LXG-F: 5’-attcacaaccgtagtatcca-3’ and LXG-R
5’-cactcagacatccatacactgacg-3’ and relative expression
values of the target gene in different cell lines were
calculated using the delta-delta CT method. For western
blotting analysis, protein extracts of stably transduced and
control cells were prepared in PBS supplemented with
Complete Mini EDTA-Free Protease Inhibitor (Roche,
Germany) through one freeze/thaw cycle. Equal amounts
of total protein, as assayed by Bradford quantification, were
separated in 12% sodium dodecyl sulfate polyacrylamide
gel and transferred to a polyvinylidene difluoride
membrane. Blocking of the membrane, dilution of mouse
anti-His antibody with the sealing solution at a ratio of
1:500, washing of the membrane with PBS, reaction with
the enzyme-labeled antimouse goat secondary antibody,
and DAB color development were performed to analyze
the expression of His-tagged HN and Noxa.
2.5. Cell viability test
The recombinant lentiviruses were added to a 96-well plate
lined with SK-BR-3 and HEK-293T cells at an MOI of 100
and cultured at 37 °C for 48 h to determine cell viability.
2.5.1. MTT assay
Cells were treated according to the manufacturer’s
instructions (Roche, the Netherlands), and the optical
density at 490 nm was detected with ELISA at various
times after infection.

2.5.2. DAPI staining assay
After centrifugation at 10,000 rpm for 5 min, harvested
transduced cells were fixed in a solution containing
3.7% formaldehyde, 0.5% Nonidet P-40, and 10 µg/mL
4’,6-diamidino-2-phenylindole (Promega, USA) in PBS.
Following 15 min of incubation in the dark, fluorescent
microscopy was used to detect apoptotic cells.
3. Results
3.1. Cloning
SOE PCR was used to connect Noxa and HN genes
flanking the 2A peptide sequence. As shown in Figure
2, PCR amplification and successful cloning of Noxa,
HN, and Surp into the lentiviral vector was confirmed by
agarose gel electrophoresis.
3.2. Expression analysis
The results of RT-PCR implied efficient viral load and
transfection of the retroviral vector pLN2AH-Surp in SKBR-3 and HEK-293T cells. Real-time quantitative PCR
was also implemented to analyze the expression level
of the two transgenes in tumor cells, which resulted in
22% expression in normal cells relative to tumor cells as
displayed in Figure 3A. Western blotting analysis further
confirmed the expression of Noxa (6 kDa) and HN (63
kDa) proteins and the proper cleavage of the 2A peptide in
both cell lines, as shown in Figure 3B.
3.3. Cell viability assay
Following transfection, we assessed the viability of the
transfected cells at various times (day 1, day 2, and day 4) to
calculate the inhibitory effect of the recombinant lentiviral
vector on tumor cell growth. Based on the results of the
cellular survival assays, as illustrated in Figure 4, it was
inferred that normal cells are hardly sensitive to the NoxaHN-expressing lentiviral vector driven by the survivin
promoter; meanwhile, a contrary response of the tumor

Figure 2. Cloning steps to construct lentiviral vector pLN2AH-Surp: (a) PCR amplification of Noxa, (b) PCR amplification of HN,
(c) PCR amplification of Surp, (d) Noxa-2A-HN, the product of SOE PCR, (e) digestion of empty pLEX vs. pLN2AH-Surp with NotI/
NrulI; M: DNA marker.

1291

RANJBAR et al. / Turk J Biol

Figure 3. Expression analysis of the Noxa-2A-HN construct: (a) relative gene expression levels of Noxa-2A-HN in normal and
tumor cells by quantitative RT-PCR indicates much higher expression of the recombinant gene in tumor cells driven by the
survivin promoter; (b) western blotting analysis of SK-BR-3 tumor cells and HEK-293T normal cells transfected with lentiviral
pLN2AH-Surp vector verified the expression of Noxa and HN and their separation by the 2A peptide in both cell lines; M: protein
marker, Lane 1: SK-BR-3 cells, Lane 2: HEK-293T cells.

Figure 4. Cell survival assay of SK-BR-3 tumor cells transfected with either pLEX or recombinant pLN2AH-Surp vector and
HEK-293T normal cells transfected with pLN2AH-Surp vector: A) MTT assay shows selective restriction of tumor cell growth
after transfection with recombinant lentiviral pLN2AH-Surp vector and trivial effect of the construct on normal cells viability;
B) DAPI staining results indicate higher apoptosis occurrence in SK-BR-3 tumor cells transfected with recombinant pLN2AH
compared to normal and pLEX transfected cancer cells.

cells to the construct eventually resulted in cell survival
reduction of 76%. The results obtained from DAPI staining
indicated that 71% of tumor cells underwent apoptosis at 4
days after transfection; conversely, only a slight percentage
of normal cells (16.5%) and pLEX transfected tumor cells
(8.2%) were apoptotic at that time.
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4. Discussion
Finding effective therapeutic platforms to treat cancer, as
a significant threat to public health, has been the primary
objective of scientists in recent years. DNA vaccines provide
a valuable means to deliver exogenous genes to malignant
or normal cells with lentiviral vectors considered as major
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candidates (Yang et al., 2014). Several suicide genes have
been reported to trigger apoptotic effects when delivered
to tumor cells. Although similar apoptotic proteins such
as Puma and t-Bid are also potent in the induction of
apoptosis (Zhang et al., 2013), Noxa is currently the only
example of this class of proteins with selective activity in
cancerous cells causing no damage to normal cells (Albert
et al., 2014). It has been proposed that Noxa may require
a more sensitive cell state wherein the expression of other
apoptotic factors such as Bax have increased (Shibue et
al., 2003; Nakajima and Tanaka, 2011; Zhang et al., 2013).
Suzuki et al. tested adenoviral, polymeric, and TAT fusion
of Noxa on different malignant cell lines, which resulted in
selective elimination of tumor cells (Suzuki et al., 2009).
Employing a tumor-specific promoter is another
method to guarantee the selective expression of transgenes
in cancerous cells and thus reduce the side-effects on normal
cells. Bao et al. proposed cancer-specific expression of the
survivin promoter to be a useful means in prognosis and
gene therapy of multiple cancers (Bao et al., 2002). Along
with Noxa, we coexpressed hemagglutinin neuraminidase
as a molecular adjuvant to impair the cell membrane and
help with the easy detection of tumor cells by the immune
system (Ni et al., 2010; Ji et al., 2013), which will play a
more important role during in vivo experiments (Ni et al.,
2011; He et al., 2014). Undesirably low expression levels of
the downstream gene in IRES-based bicistronic expression
systems, possible interference problems associated with
using two different promoters, and spatial limitations of
fusion proteins have introduced 2A peptides as our best
chance to coexpress transgenes in mammalian cells (de
Felipe et al., 1999; Luke 2012). Expression of multiple genes
linked with 2A peptides has previously been reported
in retroviral constructs (Minskaia et al., 2006; Yang et
al., 2008; Li et al., 2012; Dong et al., 2015). Since tumor
cell targeting using protein ligands may lead to systemic
immune responses, applying specificity at the genetic level
via tumor-specific genes and promoters can be very useful
to elude the damage imposed by common methods of
cancer therapy (Yamamoto and Tanigawa, 2001; Chen et
al., 2004).

In the present study, we developed a highly specific
bicistronic lentiviral vector coexpressing the suicide gene
Noxa along with HN, under the control of the tumorspecific survivin promoter. Data gathered by western
blotting and real-time PCR indicated efficient expression
of the two transgenes driven by the survivin promoter in
SK-BR-3 cancer cells and relatively low expression levels
of these proteins in normal HEK-293T cells leading to a
much lower death rate in the latter, although the general
expression level of Noxa and HN in normal cells was
higher than expected, resulting in the occurrence of a
slight percentage of apoptosis and population decrease
in normal cells, which may be interpreted as unspecific
function of HN, following the basic expression in this cell
line.
Cell survival results showed a 56% reduction in tumor
cells’ viability at 2 days after transfection, whereas after
4 days, 76% reduction was achieved, which highlighted
better results of the construct over time. The low apoptosis
and death rate of pLEX transfected control tumor cells
further supports the effectual role of the cancer-specific
elements in the tumor-killing property of the construct.
Additionally, it is noteworthy that the two analyzed cell
lines are from the same origin but not the same tissue,
presenting analysis of a broader spectrum of cells with
different markers and surface properties as potential hosts
of the construct; further examinations of systematic effect
of the recombinant lentiviral vector seems logical.
In conclusion, our results corroborate previous reports
(Suzuki et al., 2009; Nakajima and Tanaka, 2011; Albert et
al., 2014) suggesting that Noxa can be effectively used in
cancer gene therapy with negligible effect on normal cells.
The combination of Noxa, HN, and the survivin promoter
as cancer-specific elements in the novel pLN2AH-Surp
lentiviral vector proved the potential for further in vivo
and clinical experiments.
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